Integrated Alzheimer's Disease Treatment and Monitoring System
Legal Citation
Summary of the Inventive Concept
The present invention integrates cutting-edge technologies, including AI, IoT, blockchain, and machine learning, with the original patented aluminum salt-based treatment for Alzheimer's disease to create a comprehensive system for prevention, treatment, and monitoring of the disease.
Background and Problem Solved
Alzheimer's disease is a complex and debilitating condition with limited treatment options. The original patented method using aluminum salts has shown promise, but it has limitations in terms of monitoring patient response and detecting potential adverse reactions. The present invention addresses these limitations by incorporating advanced technologies to create a more effective and personalized treatment approach.
Detailed Description of the Inventive Concept
The system comprises multiple modules, including a neural network module for analyzing medical imaging data to identify β-amyloid deposition patterns, a blockchain-based data storage module for secure storage of patient data, an IoT-enabled sensor for monitoring patient vital signs, and a machine learning module for analyzing patient genetic data and medical history to predict optimal treatment regimens. The system also includes a wearable device with an integrated AI-powered algorithm for analyzing patient activity patterns and a cloud-based data analytics module for identifying trends and predicting disease progression. Additionally, the system incorporates a 3D printing module for creating customized pharmaceutical formulations.
Novelty and Inventive Step
The integration of AI, IoT, blockchain, and machine learning technologies with the original patented aluminum salt-based treatment is novel and non-obvious. The use of these technologies enables real-time monitoring, personalized treatment, and secure data storage, which is not possible with the original patented method.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, varying IoT sensor configurations, or alternative blockchain platforms. Additionally, the system could be adapted for use in treating other neurodegenerative diseases or expanded to include additional features, such as virtual reality-based therapy modules.
Potential Commercial Applications and Market
The integrated Alzheimer's disease treatment and monitoring system has significant commercial potential in the healthcare industry, particularly in the areas of personalized medicine, disease monitoring, and digital health. The system could be marketed to pharmaceutical companies, healthcare providers, and medical research institutions, offering a comprehensive solution for Alzheimer's disease treatment and management.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Neurodegenerative disease treatment, medical informatics, and personalized medicine technologies with a focus on Alzheimer's disease diagnostic and treatment systems
Person of Ordinary Skill (PHOSITA) Profile
A multidisciplinary professional with expertise in neurology, medical technology, data science, and pharmaceutical formulation, holding advanced degrees and understanding of emerging healthcare technologies
Obviousness Rationale
A PHOSITA would recognize that integrating digital monitoring and personalization technologies with existing pharmaceutical treatments represents a predictable and logical extension of current medical technology. The combination of aluminum salt-based treatment with AI, IoT, and data analytics modules follows established trends in precision medicine and digital health interventions. The technical variations represent incremental improvements that leverage known technological capabilities to enhance treatment monitoring and personalization.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,568 |
|---|---|
| Title | Treatment and prevention of Alzheimer's disease (AD) |
| Assignee(s) | Advantage Therapeutics, Inc. |